Cargando…
Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis
As a hallmark of cancer, the Warburg effect (aerobic glycolysis) confers a selective advantage for the survival and proliferation of cancer cells. Due to frequent aberration of upstream proto-oncogenes and tumor suppressors, hyperactive mammalian/mechanistic target of rapamycin (mTOR) is a potent in...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988759/ https://www.ncbi.nlm.nih.gov/pubmed/29362480 http://dx.doi.org/10.1038/s41418-017-0034-y |
_version_ | 1783329342121574400 |
---|---|
author | Sun, Qian Li, Shuzhan Wang, Yanan Peng, Haiyong Zhang, Xiying Zheng, Yu Li, Chunjia Li, Li Chen, Rongrong Chen, Xinxin Bai, Wenjing Jiang, Xiangli Liu, Liang Wei, Feng Wang, Boshi Zhang, Yu Li, Hui Ren, Xiubao Zhang, Hongbing |
author_facet | Sun, Qian Li, Shuzhan Wang, Yanan Peng, Haiyong Zhang, Xiying Zheng, Yu Li, Chunjia Li, Li Chen, Rongrong Chen, Xinxin Bai, Wenjing Jiang, Xiangli Liu, Liang Wei, Feng Wang, Boshi Zhang, Yu Li, Hui Ren, Xiubao Zhang, Hongbing |
author_sort | Sun, Qian |
collection | PubMed |
description | As a hallmark of cancer, the Warburg effect (aerobic glycolysis) confers a selective advantage for the survival and proliferation of cancer cells. Due to frequent aberration of upstream proto-oncogenes and tumor suppressors, hyperactive mammalian/mechanistic target of rapamycin (mTOR) is a potent inducer of the Warburg effect. Here, we report that overexpression of a glycolytic enzyme, phosphoglyceric acid mutase-1 (PGAM1), is critical to oncogenic mTOR-mediated Warburg effect. mTOR stimulated PGAM1 expression through hypoxia-inducible factor 1α-mediated transcriptional activation. Blockage of PGAM1 suppressed mTOR-dependent glycolysis, cell proliferation, and tumorigenesis. PGAM1 expression and mTOR activity were positively correlated in non-small cell lung cancer (NSCLC) tissues and PGAM1 abundance was an adverse predictor for patient survival. PGAM1 is thus a downstream effector of mTOR signaling pathway and mTOR-PGAM1 signaling cascade may contribute to the development of Warburg effect observed in cancer. We consider PGAM1 as a novel prognostic biomarker for NSCLC and a therapeutic target for cancer. |
format | Online Article Text |
id | pubmed-5988759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-59887592018-06-20 Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis Sun, Qian Li, Shuzhan Wang, Yanan Peng, Haiyong Zhang, Xiying Zheng, Yu Li, Chunjia Li, Li Chen, Rongrong Chen, Xinxin Bai, Wenjing Jiang, Xiangli Liu, Liang Wei, Feng Wang, Boshi Zhang, Yu Li, Hui Ren, Xiubao Zhang, Hongbing Cell Death Differ Article As a hallmark of cancer, the Warburg effect (aerobic glycolysis) confers a selective advantage for the survival and proliferation of cancer cells. Due to frequent aberration of upstream proto-oncogenes and tumor suppressors, hyperactive mammalian/mechanistic target of rapamycin (mTOR) is a potent inducer of the Warburg effect. Here, we report that overexpression of a glycolytic enzyme, phosphoglyceric acid mutase-1 (PGAM1), is critical to oncogenic mTOR-mediated Warburg effect. mTOR stimulated PGAM1 expression through hypoxia-inducible factor 1α-mediated transcriptional activation. Blockage of PGAM1 suppressed mTOR-dependent glycolysis, cell proliferation, and tumorigenesis. PGAM1 expression and mTOR activity were positively correlated in non-small cell lung cancer (NSCLC) tissues and PGAM1 abundance was an adverse predictor for patient survival. PGAM1 is thus a downstream effector of mTOR signaling pathway and mTOR-PGAM1 signaling cascade may contribute to the development of Warburg effect observed in cancer. We consider PGAM1 as a novel prognostic biomarker for NSCLC and a therapeutic target for cancer. Nature Publishing Group UK 2018-01-23 2018-06 /pmc/articles/PMC5988759/ /pubmed/29362480 http://dx.doi.org/10.1038/s41418-017-0034-y Text en © ADMC Associazione Differenziamento e Morte Cellulare 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Sun, Qian Li, Shuzhan Wang, Yanan Peng, Haiyong Zhang, Xiying Zheng, Yu Li, Chunjia Li, Li Chen, Rongrong Chen, Xinxin Bai, Wenjing Jiang, Xiangli Liu, Liang Wei, Feng Wang, Boshi Zhang, Yu Li, Hui Ren, Xiubao Zhang, Hongbing Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis |
title | Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis |
title_full | Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis |
title_fullStr | Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis |
title_full_unstemmed | Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis |
title_short | Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis |
title_sort | phosphoglyceric acid mutase-1 contributes to oncogenic mtor-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988759/ https://www.ncbi.nlm.nih.gov/pubmed/29362480 http://dx.doi.org/10.1038/s41418-017-0034-y |
work_keys_str_mv | AT sunqian phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT lishuzhan phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT wangyanan phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT penghaiyong phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT zhangxiying phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT zhengyu phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT lichunjia phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT lili phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT chenrongrong phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT chenxinxin phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT baiwenjing phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT jiangxiangli phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT liuliang phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT weifeng phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT wangboshi phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT zhangyu phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT lihui phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT renxiubao phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis AT zhanghongbing phosphoglycericacidmutase1contributestooncogenicmtormediatedtumorgrowthandconfersnonsmallcelllungcancerpatientswithpoorprognosis |